NDC-0524
Asset
Selectively binds nitrated alpha-synuclein while leaving normal protein intact to reduce the spread of pathology.
- Stage
- Preclinical
- Modality
- Antibody
- Target
- SNCA
- 3
- Indications
- 0
- Trials
- 1
- Developer
Indications
3Dementia with Lewy bodies
Preclinical, nitrasetx.com, 10 Oct 2026
Multiple system atrophy
Preclinical, nitrasetx.com, 10 Oct 2026
Parkinson's disease
Preclinical, nitrasetx.com, 10 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.